Unlike many other cancers, most pancreatic tumors are rock hard.
“That’s one reason why pancreatic cancer is one of the most lethal types of cancer,” says Kenneth Olive, PhD, associate professor of medicine and pathology & cell biology at Columbia University Vagelos College of Physicians and Surgeons and a pancreatic cancer researcher at the Herbert Irving Comprehensive Cancer Center.
“Pancreatic tumors recruit a thick layer of connective tissue called stroma that hardens the tumor and acts like a shield,” says Olive, whose previous research first uncovered how the stroma makes it difficult for chemotherapy drugs to reach malignant cells. “As a result, most chemotherapy drugs can’t build up to the levels needed to be effective.”
To Olive, that suggests, paradoxically, a longer-lived—but less toxic—drug may work better.
“For a pancreatic cancer drug to be effective, it needs to stick around long enough to seep past the stroma and accumulate in the tumor. But if it is going to persist for a long time in the blood, it can’t be as toxic to the rest of the body,” he says.
Pancreatic Ductal Adenocarcinoma
Despite some recent improvements in pancreatic cancer treatment, the five-year survival rate for individuals with this disease is only around 9%.
Testing a New Drug Combination
Olive’s latest research, which was led by Jaime Eberle-Singh, PhD, while she was a graduate student at Columbia, may have identified a good candidate. The drug, an experimental compound called PTC596 that had shown antitumor activity in mouse and human pancreatic cancer cells, seemed to have the right qualities: PTC596 has a durable half-life (most cancer drugs have a half-life of a few minutes to hours) and can evade a pump that many cancer cells use to expel drugs. “This means that any amount of drug that makes it past the barrier can target the malignant cells,” says Olive.
Based on those studies, Olive, Eberle-Singh, and their collaborators tested PTC596 in combination with gemcitabine (a first-line drug for pancreatic cancer) in genetically engineered mice with an aggressive form of pancreatic cancer that is generally resistant to chemotherapy.
The mice that were treated with the two-drug combination lived three times longer than those treated with only a single standard agent. “This result was exciting because it’s exceedingly rare for any treatment to extend survival in this gold-standard mouse model,” Olive says.
They also tested PTC596 in combination with gemcitabine and another drug commonly used to treat pancreatic cancer, nab-paclitaxel, using human pancreatic tumors grown in mice. This combination further enhanced efficacy, making the tumors shrink outright.
“Based on the drug’s safety profile and our own findings, there’s a good rationale for testing PTC596 in combination with standard therapy in patients with pancreatic cancer,” says Olive.
Microtubule Breakdown
Olive’s team also discovered that PTC596 blocks the formation of microtubules—a network of proteins involved in cell division and transport of nutrients within the cell. He demonstrated that PTC596 may act synergistically with nab-paclitaxel, another microtubule-binding agent.
“Combining different microtubule inhibitors has the potential to play an important role in the future of oncology, as there are many agents that each impact microtubules in different ways that could produce synergy,” Olive says.
Learn more: Pancreatic Cancer: Less Toxic, More Enduring Drug May Improve Therapy
The Latest on: Pancreatic cancer
[google_news title=”” keyword=”pancreatic cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Pancreatic cancer
- Hartford HealthCare awarded grant for pancreatic cancer researchon May 1, 2024 at 10:10 am
In an important effort to fight pancreatic cancer, Hartford HealthCare has been awarded a special grant by the Ron Foley Foundation.
- HealthWatch: Early Pancreatic Cancer Detection Gives Patients an Advantageon May 1, 2024 at 7:59 am
Pancreatic cancer is on the rise, especially in people younger than 55. It’s also increasing more rapidly in women than in men. More than 56 thousand ...
- Researchers find difference in pancreatic cancer cells, offering new hope for immunotherapy effectivenesson May 1, 2024 at 6:32 am
A new study has found that pancreatic cancer cells are different based on their location in the pancreas, providing new information about tumors that could lead to better targeted treatments.
- Pancreatic Cancer: Successful Trial Against Pancreatic Cancer with Defence Therapeutics' ARM-002 Anti-Cancer Vaccineon May 1, 2024 at 12:15 am
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery ...
- Study highlights differences in pancreatic cancer cells based on locationon April 30, 2024 at 9:47 pm
A new study has found that pancreatic cancer cells are different based on their location in the pancreas, providing new information about tumors that could lead to better targeted treatments.
- PanCAN Purplestride United Celebrities, Survivors, Caregivers and Supporters Nationwide at The Ultimate Walk to End Pancreatic Canceron April 30, 2024 at 10:09 am
Lisa Niemi Swayze, Eric Idle, Miss America Madison Marsh, Family of the late Jerry Springer, Team “Trek”, Little House on [...] READ MORE ...
- PurpleStride Pittsburgh charity walk raises money for pancreatic cancer researchon April 27, 2024 at 5:01 pm
The Pancreatic Cancer Action Network held Purple Stride Pittsburgh, where survivors, families, caregivers, researchers and supporters raise money through the walk. KDKA-TV's Kristine Sorensen served ...
- “Star Trek ”Actress Kitty Swink Had a 4% Survival Rate After Pancreatic Cancer — It's Been 20 Years (Exclusive)on April 25, 2024 at 8:44 am
"Seventeen days later, I came out of Cedars-Sinai with half my stomach, half my pancreas, my gallbladder gone, two feet of my intestines removed out, 28 lymph nodes removed and a 4% chance of ...
- Scottsdale pancreatic cancer survivor under the influence of hopeon April 23, 2024 at 12:10 am
The 55-year-old from Scottsdale had to undergo months of radiation, chemotherapy, then surgery. Now, he’s under the influence of hope. It wasn’t his first instinct. “I changed my mind this year,” ...
- What Is Pancreatic Cancer?on April 22, 2024 at 5:30 am
Pancreatic cancer develops when abnormal cells in the pancreas grow uncontrollably, causing symptoms like fatigue, jaundice, and urinary changes.
via Bing News